Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics (NASDAQ: ACRS) announced promising preliminary topline data for ATI-450, an oral MK2 inhibitor, from its Phase 2a trial in moderate to severe rheumatoid arthritis. This investigational drug showed significant clinical activity with sustained reductions in DAS28-CRP scores and enhanced inflammatory biomarker suppression over 12 weeks. For Q4 2020, Aclaris reported a net loss of $13.2 million, a decrease from $18.6 million in Q4 2019, along with total revenues of $1.6 million. Following a public offering in January 2021, Aclaris secured $103.5 million to strengthen its balance sheet.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at two upcoming virtual investor conferences. The presentations include the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:00 a.m. ET. Management will also be available for virtual one-on-one meetings on both days. Webcasts of the presentations can be accessed on Aclaris' website and will be archived for 30 days.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Management will engage in a virtual fireside chat at 8:00 a.m. ET and will be available for one-on-one meetings throughout the day. Investors can access a live audio webcast of the chat on the company's website, which will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, leveraging a strong R&D pipeline.
Aclaris Therapeutics (Nasdaq:ACRS) has priced its underwritten public offering of 5,483,714 shares at $17.50 each, targeting gross proceeds of approximately $96 million. The offering includes a 30-day option for underwriters to purchase an additional 822,557 shares. Expected to close on or about January 22, 2021, this capital raise, facilitated by Cantor Fitzgerald & Co. and William Blair & Company, aims to support Aclaris' ongoing clinical-stage development in immuno-inflammatory diseases.
Aclaris Therapeutics (Nasdaq: ACRS) announced its intention to conduct an underwritten public offering of its common stock, subject to market conditions. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. Cantor Fitzgerald & Co. and William Blair & Company are joint book-running managers for the offering. A shelf registration statement for these shares was filed with and declared effective by the SEC. The offering will be made via a prospectus supplement and will not constitute an offer without proper registration.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced promising topline results from a 12-week, Phase 2a trial of ATI-450, an investigational oral MK2 inhibitor, for rheumatoid arthritis. The study showed durable clinical activity, with a significant 2.0 reduction in DAS28-CRP scores and 40% of treatment subjects achieving low disease activity by week 12. ATI-450 was generally well tolerated, with no serious adverse events reported. The company plans to advance ATI-450 to Phase 2b trials and publish full data analysis in a scientific journal.
Aclaris Therapeutics (ACRS) announced the establishment of a new Scientific Advisory Board comprising leading experts in immuno-inflammatory diseases. The board includes Drs. Stanley Cohen, Marco Colonna, James Krueger, and Michael Weinblatt, who bring extensive experience in rheumatology and immunology. Additionally, Aclaris expects preliminary topline data from the ATI-450-RA-201 Phase 2a trial for rheumatoid arthritis in January 2021. This development aims to enhance Aclaris’ R&D efforts in addressing unmet medical needs in immuno-inflammatory conditions.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its participation in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 2, 2020, at 7:30 a.m. ET. Management will also be available for one-on-one virtual meetings on December 1 and 2. Investors can access a live audio webcast of the event through the company's website, with an archived version available for 30 days. Aclaris is focused on developing novel drug candidates for immuno-inflammatory diseases, supported by a robust R&D platform.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its Q3 2020 financial results and progress updates on clinical trials. The company initiated a Phase 2a trial of ATI-1777 for atopic dermatitis and dosed the first subject. Additionally, a Phase 2a trial for ATI-450 in cryopyrin-associated periodic syndrome commenced. Financial highlights included a net loss of $10.7 million for Q3 2020 compared to $55.3 million in Q3 2019, and total revenue increased to $1.4 million, up from $1.0 million. Aclaris reported cash reserves of $55.2 million as of September 30, 2020, sufficient for operations through Q1 2022.
Aclaris Therapeutics (NASDAQ: ACRS) announced the dosing of the first patient in its Phase 2a clinical trial for ATI-1777, a topical JAK 1/3 inhibitor targeting moderate to severe atopic dermatitis (AD). The trial, enrolling approximately 42 subjects across multiple sites in the U.S., aims to assess the drug's efficacy, safety, and pharmacokinetics over 28 days. The primary endpoint is the change in the Eczema Area and Severity Index (EASI) score at week 4. The trial marks a significant step in Aclaris’ development of novel treatments for immuno-inflammatory diseases.